Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis.
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis
Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain.
Generic interferon-beta
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
Study to evaluate early glatiramer acetate treatment in delaying conversion to CDMS of subjects presenting with CIS (PreCISe)
Gustatory Dysfunction in Multiple Sclerosis
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.
Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
EFNS 2012
Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: Favorable response to cancer treatment.
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis.
The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR.
Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease.
Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.

Pages